Amiodarone induced pulmonary toxicity has an incidence of about 5%-10%, and it is considered the most serious adverse effect with mortalities reaching up to 10% of the patients.
- TRADE NAMES: Aratac; Corbionax; Cordarex; Cordarone (Wyeth); Cordarone X; Pacerone (Upsher-Smith); Tachydaron
- INDICATIONS: Ventricular fibrillation, ventricular tachycardia
- CLASS: Antiarrhythmic, Antiarrhythmic class III, CYP1A2 inhibitor, CYP3A4 inhibitor
- HALF-LIFE: 26–107 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abarelix, Acebutolol, Acenocoumarol, Afatinib, Amisulpride, Amitriptyline, Amprenavir, Anisindione, Anticoagulants, Arsenic, Artemether/Lumefantrine, Asenapine, Astemizole, Atazanavir, Atorvastatin, Azoles, Betrixaban, Boceprevir, Bosentan, Carbimazole, Celiprolol, Cholestyramine, Cimetidine, Ciprofloxacin, Clopidogrel, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Colchicine, Cyclosporine, Dabigatran, Daclatasvir, Darunavir, Degarelix, Delavirdine, Dextromethorphan, Dicumarol, Digoxin, Diltiazem, Disopyramide, Dronedarone, Droperidol, Echinacea, Enoxacin, Fentanyl, Finerenone, Flecainide, Fosamprenavir, Gatifloxacin, Grapefruit Juice, Indinavir, Ledipasvir & Sofosbuvir, Lesinurad, Letermovir, Levofloxacin, Levomepromazine, Lidocaine, Lomefloxacin, Lopinavir, Loratadine, Macrolide antibiotics, Methotrexate, Moxifloxacin, Naldemedine, Nelfinavir, Nevirapine, Nilotinib, Norfloxacin, Ofloxacin, Orlistat, Oxprenolol, Pentamidine, Phenytoin, Pimavanserin, Ponesimod, Procainamide, Propranolol, Quinidine, Quinine, Quinolones, Ribociclib, Rifabutin, Rifampin, Rifapentine, Ritonavir, Ropivacaine, Rosuvastatin, Simvastatin, Sofosbuvir & Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Sotalol, Sparfloxacin, St John's Wort, Sulpiride / levosulpiride, Tacrolimus, Talazoparib, Telaprevir, Tetrabenazine, Thalidomide, Tipranavir, Trazodone, Vandetanib, Venetoclax, Verapamil, Warfarin, Zuclopenthixol
- See adverse reactions attributed to class:
PULMONARY TOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of amiodarone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/02/2024
